NSE: BETA | BSE: 531481

Download real time

1850.00 68.35 (3.84%)

76.59% Gain from 52W Low

4,515 NSE Volume

NSE 11 Apr, 2025 3:31 PM (IST)

1,867.5

Market Cap

Above industry Median

1.0

Beta 1Year

Average volatility

Beta Drugs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BETA, BSE:531481 Beta Drugs Ltd.

Search Inside the pdf :

Beta Drugs Ltd.

08 Nov 2024

1850.00

3.84%

Beta Drugs | H1FY25 Result Update

Buy: Beta Drugs Ltd.

Target

Edelweiss

Strong show in H1; near-term growth factored in

Beta Drugs Ltd. is trading above all available SMAs

Beta Drugs Ltd.

16 May 2024

1850.00

3.84%

Beta Drugs Ltd | H2FY24 Result Update

Buy: Beta Drugs Ltd.

Target

Edelweiss

Deepening its roots in the market

Beta Drugs Ltd. is trading above all available SMAs

Beta Drugs Ltd.

03 Sep 2023

1850.00

3.84%

Beta Drugs | The CUB Series

Buy: Beta Drugs Ltd.

Edelweiss

Beta Drugs (BETADR) is one of the leading players in the domestic oncology space and ranks among the top 10 in the cytotoxic market.

Beta Drugs Ltd. is trading above all available SMAs

Beta Drugs Ltd.

24 Mar 2023

1850.00

3.84%

Beta Drugs | Plant Visit Note

Not Rated: Beta Drugs Ltd.

Edelweiss

We visited Beta Drugs' (BETADR) formulation facilities located at Baddi and Mohali (Chandigarh), which have been expanded and upgraded, and the management.

Beta Drugs Ltd. is trading above all available SMAs

Is Beta Drugs Ltd. worth buying?

63 Votes:

Buy 77.78%

Sell 12.7%

Hold 9.52%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf link

Buy SEE REPORTS >

pdf link